Evidence map›Paper›PMID 40531822›Full record

ArticleOcular immunology and inflammation2025

Tocilizumab for Silicone Oil-Induced Recalcitrant Cystoid Macular Edema in a Patient with Recurrent Acute Retinal Necrosis-Associated Retinal Detachment.

Warren W Pan, Mahsaw Mansoor, David Riccardi, Jacqueline A Madison, Thomas J Wubben, Shilpa Kodati, Jason Miller

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular immunology and inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Warren W PanDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
Mahsaw MansoorDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
David RiccardiDivision of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Jacqueline A MadisonDivision of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Thomas J WubbenDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
Shilpa KodatiDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
Jason MillerDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-2784-9560

Funding

Lipid Trafficking and Metabolism in the Retinal Pigment EpitheliumK08EY033420 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason Matthew-Lewis Miller · 2022 to 2026
$1.2M
NEI NIH HHS K08 EY033420
6 · The paper itself

Abstract

purposeWe report a case of refractory silicone oil-induced cystoid macular edema in a patient with recurrent acute retinal necrosis-related retinal detachments successfully treated with tocilizumab without silicone oil removal nor reactivation of the acute retinal necrosis.

methodsSingle-patient case report.

resultsA monocular patient with recurrent acute retinal necrosis-related retinal detachments necessitating indefinite silicone oil tamponade developed intractable cystoid macular edema immediately after silicone oil placement that was unresponsive to multiple therapies over nearly a year. After a single dose of tocilizumab, the patient demonstrated significant clinical improvement with resolution of the macular edema and reduction in petaloid macular leakage on fluorescein angiography. With continued tocilizumab treatment, silicone oil tamponade could be maintained, and no reactivation of acute-retinal necrosis was noted.

conclusionThis case represents the first documented successful use of tocilizumab in treating silicone oil-induced recalcitrant cystoid macular edema. When silicone oil cannot be removed from an eye and when steroids risk reactivating viral retinal disease, tocilizumab may offer a safe and effective treatment alternative for such macular edema.

Indexed as

Antibodies, Monoclonal, HumanizedMacular EdemaRetinal DetachmentRetinal Necrosis Syndrome, AcuteSilicone OilsEndotamponadeFemaleFluorescein AngiographyFundus OculiHumansIntravitreal InjectionsMaleMiddle AgedRecurrenceTomography, Optical CoherenceVisual AcuityAntibodies, Monoclonal, HumanizedSilicone OilstocilizumabAcute retinal necrosiscystoid macular edemaretinal detachmentsilicone oiltocilizumab

Identifiers

PMID40531822
PMCPMC12255164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.